GlassScriptPhysician profile
Dmitri Souza
NPI 1578718821
$60,561.92
in general payments reported to CMS, 2019-2025
28 companies · $5,148 in 2025
The $5,148 reported for 2025 was more than what 93% of Pain Medicine (Anesthesiology) providers received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $454 · 2020: $24.88 · 2021: $23K · 2022: $8,982 · 2023: $12K · 2024: $11K · 2025: $5,148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $26K · Food and Beverage: $1,455.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $26,468.75 |
| Food and Beverage | $1,455.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $53,185.42 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Allergan, INC. | $5,624.43 | 2021 | |
| Stimwave Technologies Incorporated | $325.41 | 2019 | |
| Medtronic, INC. | $209.00 | 2024 | Synchromedii, Intellis Adaptivestim |
| Pfizer INC. | $153.11 | 2019-2025 | |
| Nevro Corp. | $127.63 | 2019-2024 | Senza |
| Collegium Pharmaceutical, INC. | $116.27 | 2022-2025 | Belbuca, Xtampza |
| Averitas Pharma INC. | $93.44 | 2024-2025 | Qutenza |
| Lilly USA, LLC | $83.33 | 2021-2024 | Reyvow, Emgality |
| Lundbeck LLC | $81.29 | 2023-2025 | Vyepti |
| Abbott Laboratories | $66.13 | 2020-2025 | Eterna, Proclaim |
| Vertex Pharmaceuticals Incorporated | $61.60 | 2025 | |
| Grt US Holding, INC. | $61.29 | 2021-2022 | |
| Spr Therapeutics, INC | $57.58 | 2021 | |
| Amgen INC. | $47.61 | 2020-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $45.73 | 2019-2021 | |
| Assertio Therapeutics, INC. | $45.55 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $32.33 | 2022 | |
| Depuy Synthes Sales INC. | $26.21 | 2024 | Orthovisc, Monovisc |
| Boston Scientific Corporation | $19.75 | 2025 | General - Pain Management |
| Biohaven Pharmaceuticals, INC. | $18.08 | 2021 | |
| Nalu Medical, INC. | $16.62 | 2022 | |
| Curonix LLC | $15.07 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Azurity Pharmaceuticals, INC. | $14.09 | 2023 | Horizant |
| Almatica Pharma LLC | $12.08 | 2021 | |
| Supernus Pharmaceuticals, INC. | $11.56 | 2019 | |
| Mdd US Operations, LLC | $11.31 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dmitri Souza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.